JP2003516930A - 転移性疾患の治療 - Google Patents

転移性疾患の治療

Info

Publication number
JP2003516930A
JP2003516930A JP2001516518A JP2001516518A JP2003516930A JP 2003516930 A JP2003516930 A JP 2003516930A JP 2001516518 A JP2001516518 A JP 2001516518A JP 2001516518 A JP2001516518 A JP 2001516518A JP 2003516930 A JP2003516930 A JP 2003516930A
Authority
JP
Japan
Prior art keywords
epha2
cells
antibody
metastatic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516930A5 (cg-RX-API-DMAC7.html
Inventor
スコット キンチ,マイケル
イー. キルパトリック,キャサリン
ディー. ザンテク,ニコル
ダブリュ. ヘイン,パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22529456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003516930(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, Purdue Research Foundation filed Critical Glaxo Group Ltd
Publication of JP2003516930A publication Critical patent/JP2003516930A/ja
Publication of JP2003516930A5 publication Critical patent/JP2003516930A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2001516518A 1999-08-17 2000-08-17 転移性疾患の治療 Pending JP2003516930A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925899P 1999-08-17 1999-08-17
US60/149,258 1999-08-17
PCT/US2000/022670 WO2001012172A1 (en) 1999-08-17 2000-08-17 Treatment of metastatic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007211840A Division JP2007306938A (ja) 1999-08-17 2007-08-15 転移性疾患の治療

Publications (2)

Publication Number Publication Date
JP2003516930A true JP2003516930A (ja) 2003-05-20
JP2003516930A5 JP2003516930A5 (cg-RX-API-DMAC7.html) 2008-06-05

Family

ID=22529456

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001516518A Pending JP2003516930A (ja) 1999-08-17 2000-08-17 転移性疾患の治療
JP2007211840A Pending JP2007306938A (ja) 1999-08-17 2007-08-15 転移性疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007211840A Pending JP2007306938A (ja) 1999-08-17 2007-08-15 転移性疾患の治療

Country Status (10)

Country Link
EP (2) EP2289940A3 (cg-RX-API-DMAC7.html)
JP (2) JP2003516930A (cg-RX-API-DMAC7.html)
AT (1) ATE324877T1 (cg-RX-API-DMAC7.html)
AU (1) AU6784400A (cg-RX-API-DMAC7.html)
CA (1) CA2380888A1 (cg-RX-API-DMAC7.html)
DE (1) DE60027768T2 (cg-RX-API-DMAC7.html)
DK (1) DK1242060T3 (cg-RX-API-DMAC7.html)
ES (1) ES2261230T3 (cg-RX-API-DMAC7.html)
PT (1) PT1242060E (cg-RX-API-DMAC7.html)
WO (1) WO2001012172A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500021A (ja) * 2003-11-20 2008-01-10 メディミューン,インコーポレーテッド EphA2アゴニストモノクローナル抗体およびその使用法
JP2009543575A (ja) * 2006-07-18 2009-12-10 サノフイ−アベンテイス 癌治療用対epha2アンタゴニスト抗体
WO2014126160A1 (ja) * 2013-02-13 2014-08-21 国立大学法人東京大学 がんの検査方法及び検査用キット
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 EphA2 N末端フラグメント抗体

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
DZ3332A1 (fr) 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
NZ537458A (en) * 2001-01-23 2007-02-23 Primagen Holding B Means and methods for treatment evaluation
EP1225233A3 (en) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Means and methods for treatment evaluation
EP1298221A1 (en) * 2001-09-28 2003-04-02 PrimaGen Holding B.V. Means and methods for treatment evaluation
DE60234782D1 (de) * 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
AU2003215190A1 (en) * 2002-02-15 2003-09-09 Millennium Pharmaceuticals, Inc. Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
EP1519956B1 (en) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
EP1505999A4 (en) 2002-05-23 2009-07-08 Purdue Research Foundation LOW-MOLECULAR PROTEIN-TYROSINE PHOSPHATASE (LMW-PTP) AS DIAGNOSTIC AND THERAPEUTIC TARGET
AU2004210463B2 (en) * 2003-02-07 2009-07-16 Ludwig Institute For Cancer Research Limited Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
EP1617864A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
CA2525929A1 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
WO2005016381A2 (en) * 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
BRPI0607450A2 (pt) 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
US20090022760A1 (en) 2006-09-12 2009-01-22 Alphavax Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗epha2抗体
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US20210268098A1 (en) 2018-08-03 2021-09-02 Uab Research Foundation Methods and compositions for alphavirus vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07132084A (ja) * 1992-11-24 1995-05-23 Bristol Myers Squibb Co Her4ヒト受容体チロシンキナーゼ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
ES2242437T3 (es) * 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07132084A (ja) * 1992-11-24 1995-05-23 Bristol Myers Squibb Co Her4ヒト受容体チロシンキナーゼ

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500021A (ja) * 2003-11-20 2008-01-10 メディミューン,インコーポレーテッド EphA2アゴニストモノクローナル抗体およびその使用法
JP4860477B2 (ja) * 2003-11-20 2012-01-25 メディミューン,エルエルシー EphA2アゴニストモノクローナル抗体およびその使用法
JP2009543575A (ja) * 2006-07-18 2009-12-10 サノフイ−アベンテイス 癌治療用対epha2アンタゴニスト抗体
WO2014126160A1 (ja) * 2013-02-13 2014-08-21 国立大学法人東京大学 がんの検査方法及び検査用キット
JP2014178301A (ja) * 2013-02-13 2014-09-25 Univ Of Tokyo がんの検査方法及び検査用キット
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 EphA2 N末端フラグメント抗体

Also Published As

Publication number Publication date
DK1242060T3 (da) 2006-08-21
JP2007306938A (ja) 2007-11-29
PT1242060E (pt) 2006-08-31
EP1242060A1 (en) 2002-09-25
WO2001012172B1 (en) 2001-08-16
WO2001012172A1 (en) 2001-02-22
DE60027768D1 (de) 2006-06-08
EP1242060B1 (en) 2006-05-03
ATE324877T1 (de) 2006-06-15
EP2289940A3 (en) 2011-09-21
AU6784400A (en) 2001-03-13
CA2380888A1 (en) 2001-02-22
DE60027768T2 (de) 2007-04-05
EP1242060A4 (en) 2003-09-24
ES2261230T3 (es) 2006-11-16
EP2289940A2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
US8591887B2 (en) EPHA2 as a therapeutic target for cancer
EP1242060B1 (en) Treatment of metastatic disease
JP7316862B2 (ja) 小細胞肺癌に対する標的療法
JP4726777B2 (ja) 癌疾患修飾抗体
AU2011200789B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
JP5367776B2 (ja) Cd44表面発現を示している細胞の結合検定法及び単離法
US20030082188A1 (en) Treatment of prostate cancer by inhibitors of NCAM2
JP2012031183A (ja) Cd44の表面発現を証明する細胞の細胞毒性媒介
CN101107267A (zh) 对表面表达有mcsp的细胞的细胞毒性的介导
JP2008545615A (ja) Cd63の表面発現を証明する細胞の細胞毒性仲介
US20240174762A1 (en) Methods, compositions and uses for targeting sema7a in the diagnosis and treatment of health conditions
AU2006202023B2 (en) Treatment of metastatic disease
EP1695702A2 (en) Treatment of metastatic disease
US20040048817A1 (en) Methods of immunotherapy and diagnosis
CN113773389B (zh) 鼠抗人胸苷激酶1单克隆抗体及其制药用途
WO2012133994A1 (ko) Pauf 및 그의 결합 파트너를 상호작용을 이용한 암 치료제의 스크리닝 방법
US20040022786A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
HK1121376A (en) Cancerous disease modifying antibody

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20040524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040524

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070815

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111206